Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
FTC Approves Amended Final Order Settling Charges Of Teva Pharmaceutical Industries Ltd's Acquisition Of Cephalon, Inc-DJ
Dow Jones reported that Federal Trade Commission has approved an amended final order settling charges that Teva Pharmaceutical Industries, Ltd.'s proposed acquisition of rival Cephalon, Inc. would have been anticompetitive in the markets for several current and future generic drugs. The final amended FTC order resolving the charges requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals, Inc. It also requires Teva to enter into a supply agreement that will allow Par to sell a generic version of Cephalon's wakefulness drug Provigil in 2012, and contains additional terms detailed in a statement issued by Bureau of Competition Director Richard Feinstein.
Latest Developments for Teva Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402
- FDA Approves New Drug Application For Teva Pharmaceutical Industries Ltd's Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets For Prevention Of Pregnancy
- Teva Pharmaceutical Industries Ltd And H. Lundbeck A/S Announces Results Of Azilect
- Teva Pharmaceutical Industries Ltd Reaffirms FY 2013 Guidance; Comments On H1, H2 Revenue Guidance-Conference Call
- Share this
- Link this
- Digg this


Follow Reuters